Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPB-01 for Bullous Pemphigoid
NCT00809822Phase 2Completed
- Sponsor
- Nihon Pharmaceutical
- Start
- Nov 2008
- Primary completion
- Oct 2010
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of intravenous immunoglobulin G in Bullous Pemphigoid (BP) (2 arms), sponsored by Nihon Pharmaceutical. Primary endpoints: Skin lesion area at 57 days, Number of new blisters at 57 days and 7 more. Started Nov 2008; status: completed.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on NCT00809822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00809822.